EU-FDA MRA to be expanded
Recommendation

1/2 December 2026
How to implement EU-GMP Chapter 8
It has not yet been fully implemented - and we are already talking about an enlargement. The Mutual Recognition Agreement (MRA) with the USA was extended in 2018 to include further countries: Czech Republic, Greece, Hungary, Romania, Ireland, Lithuania, Portugal, Belgium, Denmark, Estonia, Finland, Latvia. Some countries, including Germany, are still not part of the agreement. (Here you will find an overview of the current status). By 15 July 2019, however, all authorities and countries should have been approved and included.
Now, there are already discussions about extending the scope of the MRA. It is to be extended to veterinary medicinal products in the medium term. Later, until 2022, the MRA is to be extended to include joint inspections of production facilities for human vaccines and plasma derivatives. An action plan will be drawn up for this purpose in 2019. This is stated in an interim report of the Executive Working Group EWG.
Related GMP News
02.11.2026Singapore Added to the List of Recognised third Countries for Importation of APIs
02.11.2026Failed GMP Training in 2026: Further GMP Training Deficiencies in FDA Warning Letters
21.10.2026Switzerland: GMP Compliance by Foreign Manufacturers
14.10.2026EU Pharma Package: Council Adopts New Rules
14.10.2026ICH Publishes New Training Material for Quality Guidelines
14.10.2026WHO issues Draft Guidance on Quality Risk Management


